Skip to main content

Table 2 The values of the respective SF-36 scores in patients randomly treated with omeprazole and the placebo prior to the study and after two weeks of therapy

From: Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey

SF-36 scales

Omeprazole (n = 23)

Placebo (n = 25)

 

At baseline

After 2 weeks

At baseline

After 2 weeks

Total average SF-36 score

53.9

(46.6-61.2)

63.3*#

(56.2-70.4)

50.0

(43.7-56.3)

52.9*

(45.3-60.6)

Physical functioning

63.5

(54.1-72.9)

68.1 #

(57.8-78.3)

56.4

(49.2-63.6)

61.6

(52.9-70.3)

Limitations due to physical health problems

34.8

(15.8-53.7)

59.8#

(39.5-80.1)

35.0

(17.4-52.6)

37.0

(20.7-53.4)

Bodily pain

50.5

(39.8-61.3)

66.6*#

(55.8-77.5)

41.3

(32.8-49.8)

49.4*

(36.2-62.6)

General health perception

45.9

(37.4-54.3)

50.4*

(46.2-54.7)

41.0

(34.5-47.5)

43.0*

(37.1-49.0)

Physical health component (summarized)

48.7

(38.9-58.4)

61.2*#

(52.4-74.4)

43.4

(35.9-50.9)

47.8*

(47.3-66.2)

Limitations due to personal and emotional problems

65.2

(46.5-83.9)

75.4

(60.2-90.6)

60.0

(41.4-78.6)

53.3

(34.7-72.0)

Energy/fatigue (vitality)

52.4

(44.7-60.1)

57.6

(49.8-65.4)

46.4

(40.3-52.5)

52.6#

(44.4-60.8)

Emotional well-being

52.7

(47.9-57.5)

62.3#

(54.8-69.8)

53.9

(49.1-58.8)

57.1

(49.4-64.9)

Social functioning

61.4

(49.8-73.1)

71.2

(60.7-81.7)

64.5

(62.4-76.6)

64.0

(51.3-76.7)

Mental health component (summarized)

57.9

(50.0-65.9)

66.6#

(58.8-74.4)

56.2

(48.6-63.8)

56.8

(47.3-66.2)

  1. data presented as mean and 95% CI
  2. *-p < 0.05; statistical significance of difference using Fisher's Least Significant Difference (LSD) post hoc test between omeprazole and placebo groups;
  3. #-statistical significance of difference using Fisher's Least Significant Difference (LSD) post hoc test for comparing the values at baseline and after respective therapy.